Gilead Reports ‘Mildly Disappointing’ Quarterly Results With An Unexpected High Point
Investor's Business DailyGilead had a “mildly disappointing” fourth quarter that featured two high-profile misses from HIV drugs. GILD stock hit a four-month low.
The post Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point appeared …